Cytosorbents Co. (NASDAQ:CTSO) Shares Sold by Sargent Investment Group LLC

Sargent Investment Group LLC cut its position in Cytosorbents Co. (NASDAQ:CTSO - Free Report) by 23.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,248,863 shares of the medical research company's stock after selling 377,384 shares during the period. Sargent Investment Group LLC owned 2.28% of Cytosorbents worth $1,136,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, Geode Capital Management LLC increased its position in shares of Cytosorbents by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company's stock valued at $701,000 after purchasing an additional 32,415 shares during the last quarter. 32.87% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

CTSO has been the topic of a number of recent analyst reports. HC Wainwright reissued a "neutral" rating and issued a $1.00 price objective on shares of Cytosorbents in a research report on Monday, November 11th. StockNews.com initiated coverage on shares of Cytosorbents in a research report on Thursday. They issued a "hold" rating on the stock. Finally, D. Boral Capital reaffirmed a "buy" rating and issued a $10.00 target price on shares of Cytosorbents in a research report on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Cytosorbents has an average rating of "Moderate Buy" and a consensus target price of $4.67.

Cytosorbents Stock Performance

NASDAQ:CTSO traded down $0.03 during trading hours on Friday, reaching $1.02. 71,313 shares of the company's stock were exchanged, compared to its average volume of 107,929. The firm has a market capitalization of $55.77 million, a price-to-earnings ratio of -2.83 and a beta of 0.61. The company has a 50-day moving average of $0.96 and a 200 day moving average of $1.04. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. Cytosorbents Co. has a 1-year low of $0.70 and a 1-year high of $1.59.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The medical research company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.03). The business had revenue of $9.39 million for the quarter, compared to analyst estimates of $10.14 million. Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%. During the same quarter in the prior year, the company earned ($0.21) EPS. Research analysts anticipate that Cytosorbents Co. will post -0.3 EPS for the current year.

Cytosorbents Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.